Is Syngene International (SYNGENE) overvalued or fairly valued?

MarketChacha shows Syngene International's valuation in context — a forward P/E of about 37.1, a price-to-book of about 3.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Syngene International's revenue?

Syngene International reported revenue of ₹3,424 Cr for FY2026, with net profit of ₹305 Cr, per official filings.

What is the share price of Syngene International (SYNGENE)?

Syngene International last traded at ₹397.50 (+3.0% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Syngene International

SYNGENE · NSE · Pharma/CRO · India

Snapshot

TickerSYNGENE

ExchangeNSE

SectorPharma/CRO

IndustryDiagnostics & Research

CountryIndia

Employees6,692

HeadquartersBengaluru, India

Websitewww.syngeneintl.com

Filings tracked6

About Syngene International

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Who owns it

Promoters52.8%
Institutions38.7%
Public & other8.5%

81 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 6.1 points over the period — profitability is trending down.

Net margin trend14.5% → 8.5%

Margin has compressed by about 6.1 points over the period — profitability is trending down.

Growth qualityrev 4% · PAT -9%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹926 Cr · EPS 2.03

Est. earnings growth +56.4%

Next fiscal year

Rev ₹4,204 Cr · EPS 10.71

Est. earnings growth +41.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹3,739 Cr

Net margin

8.5%

Revenue CAGR (3y)

+5.4%

Profit CAGR (3y)

-12.0%

Net profit (FY2026)

₹317 Cr

Ask MarketChacha about SYNGENE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about SYNGENE

Why did Syngene International sink ~9% to a 52-week low today?c/indianmarkets · 7/30/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,739 Cr	₹317 Cr	8.5%
FY2025	₹3,642 Cr	₹496 Cr	13.6%
FY2024	₹3,489 Cr	₹510 Cr	14.6%
FY2023	₹3,193 Cr	₹464 Cr	14.5%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹736 Cr	₹-9 Cr	-1.2%
Q4 FY26	₹1,037 Cr	₹148 Cr	14.3%
Q3 FY26	₹917 Cr	₹15 Cr	1.6%
Q2 FY26	₹911 Cr	₹67 Cr	7.4%
Q1 FY26	₹875 Cr	₹87 Cr	9.9%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Change in Management
Resignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the Company w.e.f. the close of business ....
BSE9/21/2026
Communication Regarding Remittance Of Final Dividend For The FY 2025-26
Communication regarding remittance of final dividend for the FY 2025-26
BSE9/10/2026
Grant Of Performance Share Units Under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ('Plan')
Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ("Plan")
BSE9/1/2026
Investor Presentation
Investor Presentation
BSE7/29/2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 33rd Annual General Meeting
BSE7/29/2026material
Change in Management
Resignation of Independent Director
BSE7/29/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.